FDA Approves Zevaskyn: First Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

The Food and Drug Administration (FDA) has approved Zevaskyn, a gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The FDA approval marks Zevaskyn as the first gene therapy available for this condition. Zevaskyn is designed to promote wound healing and relieve pain in patients with RDEB. RDEB is a rare genetic disorder characterized by fragile skin that blisters and tears easily. The gene therapy aims to address the underlying genetic defect that causes the disease. The treatment offers a new therapeutic option for individuals affected by this debilitating condition.

Newsflash | Powered by GeneOnline AI
Date: April 29, 2025

Related posts:

STAT’s D.C. Diagnosis Newsletter Delivers Twice-Weekly Health Policy Insights Teenage years crucial for depression intervention, study finds Justice Department Sues Three Medicare Advantage Insurers and Brokerages Alleging Illegal Kickback Scheme Investigation Launched into Import Surge Impact on National Security: Focus on Potential Threat to Critical Domestic Industries

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後